NO20054723L - Behandling av proliferative sykdommer med epofilonderivater og straling - Google Patents

Behandling av proliferative sykdommer med epofilonderivater og straling

Info

Publication number
NO20054723L
NO20054723L NO20054723A NO20054723A NO20054723L NO 20054723 L NO20054723 L NO 20054723L NO 20054723 A NO20054723 A NO 20054723A NO 20054723 A NO20054723 A NO 20054723A NO 20054723 L NO20054723 L NO 20054723L
Authority
NO
Norway
Prior art keywords
treatment
radiation
epophilone
derivatives
proliferative diseases
Prior art date
Application number
NO20054723A
Other languages
English (en)
Norwegian (no)
Inventor
Martin Pruschy
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20054723L publication Critical patent/NO20054723L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Radiation-Therapy Devices (AREA)
NO20054723A 2003-03-14 2005-10-13 Behandling av proliferative sykdommer med epofilonderivater og straling NO20054723L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0305928.4A GB0305928D0 (en) 2003-03-14 2003-03-14 Organic compounds
PCT/EP2004/002610 WO2004080458A1 (fr) 2003-03-14 2004-03-12 Traitement de maladies proliferatives au moyen de derives d'epothilone et d'une exposition a des rayonnements

Publications (1)

Publication Number Publication Date
NO20054723L true NO20054723L (no) 2005-10-13

Family

ID=9954825

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054723A NO20054723L (no) 2003-03-14 2005-10-13 Behandling av proliferative sykdommer med epofilonderivater og straling

Country Status (25)

Country Link
US (2) US20070129411A1 (fr)
EP (1) EP1605937B1 (fr)
JP (1) JP4927530B2 (fr)
KR (1) KR20050109988A (fr)
CN (2) CN1758908A (fr)
AT (1) ATE491450T1 (fr)
AU (1) AU2004218927A1 (fr)
BR (1) BRPI0408366A (fr)
CA (1) CA2519037A1 (fr)
DE (1) DE602004030545D1 (fr)
ES (1) ES2358109T3 (fr)
GB (1) GB0305928D0 (fr)
IL (1) IL170632A (fr)
IS (1) IS8059A (fr)
MA (1) MA27634A1 (fr)
MX (1) MXPA05009808A (fr)
NO (1) NO20054723L (fr)
NZ (1) NZ542305A (fr)
PL (1) PL1605937T3 (fr)
PT (1) PT1605937E (fr)
RU (1) RU2381799C2 (fr)
TN (1) TNSN05226A1 (fr)
TW (1) TWI358295B (fr)
WO (1) WO2004080458A1 (fr)
ZA (1) ZA200506942B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242469B1 (en) 1996-12-03 2001-06-05 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
WO2004018478A2 (fr) 2002-08-23 2004-03-04 Sloan-Kettering Institute For Cancer Research Synthese d'epothilones, leurs intermediaires, leurs analogues et leurs utilisations
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP1640004A1 (fr) * 2004-09-24 2006-03-29 Schering Aktiengesellschaft Utilisation des epothilones pour le traitement des metastases osseuses ou du cancer des os
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
CN103037903A (zh) 2010-05-18 2013-04-10 天蓝制药公司 用于治疗自身免疫性疾病或其它疾病的组合物和方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6033645A (en) * 1996-06-19 2000-03-07 Unger; Evan C. Methods for diagnostic imaging by regulating the administration rate of a contrast agent
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
US6242469B1 (en) * 1996-12-03 2001-06-05 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6605599B1 (en) * 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
JP2001288097A (ja) * 2000-04-07 2001-10-16 Pg-Txl Co Lp 水溶性パクリタキセル誘導体
PL207720B1 (pl) * 2001-01-25 2011-01-31 Bristol Myers Squibb Co Sposób przygotowania preparatu farmaceutycznego i jego zastosowanie, farmaceutyczny produkt oraz sposób wytwarzania kompozycji farmaceutycznej
CA2440555A1 (fr) * 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combinaison d'analogues d'epothilones et d'agents chimiotherapeutiques servant au traitement de maladies proliferatives

Also Published As

Publication number Publication date
RU2005131723A (ru) 2007-08-20
BRPI0408366A (pt) 2006-03-21
IL170632A (en) 2012-01-31
WO2004080458A1 (fr) 2004-09-23
TWI358295B (en) 2012-02-21
CN1758908A (zh) 2006-04-12
NZ542305A (en) 2009-03-31
ZA200506942B (en) 2006-07-26
TW200505444A (en) 2005-02-16
GB0305928D0 (en) 2003-04-23
PT1605937E (pt) 2011-03-17
ATE491450T1 (de) 2011-01-15
RU2381799C2 (ru) 2010-02-20
DE602004030545D1 (de) 2011-01-27
MA27634A1 (fr) 2005-11-01
IS8059A (is) 2005-10-04
CN101804050A (zh) 2010-08-18
HK1086493A1 (en) 2006-09-22
JP4927530B2 (ja) 2012-05-09
ES2358109T3 (es) 2011-05-05
US20070129411A1 (en) 2007-06-07
AU2004218927A1 (en) 2004-09-23
US20120053559A1 (en) 2012-03-01
EP1605937B1 (fr) 2010-12-15
EP1605937A1 (fr) 2005-12-21
KR20050109988A (ko) 2005-11-22
TNSN05226A1 (en) 2007-06-11
JP2006520353A (ja) 2006-09-07
PL1605937T3 (pl) 2011-05-31
CA2519037A1 (fr) 2004-03-23
MXPA05009808A (es) 2005-10-26

Similar Documents

Publication Publication Date Title
NO20055894L (no) Fremgangsmater og blandinger for behandling av amyloidrelatertere sykdommer
IL260127B (en) mek inhibitors and methods of using them
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
ATE411022T1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
TW200600087A (en) Methods and compositions for treating amyloid-related diseases
CY2015003I2 (el) Φαρμακευτικες συνθεσεις για θεραπεια καρκινου
MXPA05009595A (es) Compuestos 7-amino-isoindolilo y sus usos farmaceuticos.
IL180979A (en) Isoindulin compounds and their use
BR0312573A (pt) Derivados de fenil-[4-(3-fenil-1h-pirazol-4-il)-pirimidin-2-il]-amina
ATE370139T1 (de) Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebs
NO20082594L (no) Pyrimidinylbenzotiofenforbindelser
ATE408601T1 (de) Fredericamycin-derivate
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
IS7691A (is) Lyfjasamsetningar til að meðhöndla æxli
DE602004020070D1 (de) Thienopyrimidin-derivate als kaliumkanal-inhibitoren
EA200701930A1 (ru) Производные пиримидина для лечения гиперпролиферативных нарушений
WO2007016338A3 (fr) Utilisation d’inhibiteurs de la chk2 kinase pour le traitement du cancer
IS8059A (is) Meðhöndlun fjölgunarsjúkdóma með epóþílónafleiðumog geislun
WO2007050655A3 (fr) Combinaison d'inhibiteurs de l'histone desacetylase et d'un rayonnement
DK1551850T3 (da) 2"-oxo-voruscharin og derivater deraf
UA96742C2 (en) Mek inhibitors and use thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application